John Tod Isaacs

This inventor holds 22 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Prodrug Development. Top assignees: Johns Hopkins University, Genspera, Inc., University of Victoria. Active years: 2001-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Tod Isaacs. Retrieved from https://idiyas.com/inventor/john-tod-isaacs

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 5)

% Patents Active = 50.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 2.8

ph-index = 9

Forward Citations = 229(Granted Patents)

Location History:

Baltimore, MD (US) (2001 - 2003)
Pheonix, MD (US) (2003 - 2014)
Phoenix, MD (US) (2001 - 2021)

Company Filing History:

11 out of 3,803

Johns Hopkins University

University of Victoria

University of Victoria Innovatiion and Development Corporation

patent

6. 3 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2026

Loading Chart...

Areas of Expertise:

Prodrug

Tumor Activation

Peptide Prodrugs

Cancer Detection

Tissue Specific

Protease Activation

Gene Therapy

Metastasis Suppressor

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12691158 - ALBUMIN-PROAEROLYSIN PRODRUGS (2026-07-28),

2. 10967046 - Albumin-proaerolysin prodrugs (2021-04-06),

3. 10596226 - Albumin-proaerolysin prodrugs (2020-03-24),

4. 8957016 - Tumor activated prodrugs (2015-02-17),

5. 8822406 - Tumor activated prodrugs (2014-09-02),

6. 8772226 - Methods and compositions for the detection of cancer (2014-07-08),

7. 8669231 - Activation of peptide prodrugs by hK2 (2014-03-11),

8. 8450280 - Activation of peptide prodrugs by hK2 (2013-05-28),

9. 7906477 - Activation of peptide prodrugs by hK2 (2011-03-15),

10. 7838266 - Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer (2010-11-23),

11. 7767648 - Tissue specific prodrugs (2010-08-03),

12. 7745395 - Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer (2010-06-29),

13. 7635682 - Tumor activated prodrugs (2009-12-22),

14. 7468354 - Tissue specific prodrugs (2008-12-23),

15. 7282476 - Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer (2007-10-16),

Title: John Tod Isaacs: Innovating Cancer Treatment Through Patented Technologies

Introduction

John Tod Isaacs is a prominent inventor based in Phoenix, MD, known for his significant contributions to the field of cancer treatment. With a remarkable portfolio of 21 patents, Isaacs has dedicated his career to developing innovative solutions aimed at improving cancer therapies and patient outcomes.

Latest Patents

One of Isaacs' latest inventions involves albumin-proaerolysin prodrugs, which specifically address cancer treatment. This invention presents compositions and methods designed to effectively treat cancer utilizing albumin-proaerolysin prodrugs. Notably, the prodrug composition includes a prostate-specific antigen (PSA)-activated pro-aerolysin (PA), where a PSA cleavable linker replaces the native furin cleavage site within PA. The composition also incorporates human serum albumin (HSA) or a fragment fused to the N-terminus of the PSA-activated PA, showcasing Isaacs’ innovative approach to enhancing drug efficacy.

Career Highlights

Throughout his career, John Tod Isaacs has collaborated with renowned institutions such as The Johns Hopkins University and Genspera, Inc. His work in these esteemed organizations has provided a platform for advancing cancer research and patenting groundbreaking technologies. Isaacs’ dedication to innovation is evident in his extensive patent portfolio, which continues to grow as he explores new avenues for cancer treatment.

Collaborations

Isaacs has had the opportunity to collaborate with notable figures in his field, including Samuel Ray Denmeade and Hans Lilja. These collaborative efforts have enriched his research and fostered advancements in cancer therapies, further solidifying his reputation as a leading inventor in the industry.

Conclusion

John Tod Isaacs stands out as a visionary inventor in the realm of cancer treatment innovations. His contributions, as reflected in his 21 patents, demonstrate a commitment to leveraging scientific advancements for improved patient care. As his work continues to evolve, Isaacs remains a pivotal figure in the ongoing battle against cancer, dedicated to transforming the future of treatment options.

Profile summary based on public USPTO records.